Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2003-02-04
2004-12-07
Kifle, Bruck (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C514S010100, C514S011400, C514S018700, C514S019300
Reexamination Certificate
active
06828301
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates in general to pharmaceutical compositions of hepatitis C viral protease inhibitors having improved bioavailability, and methods of using these compositions for inhibiting the replication of the hepatitis C virus (HCV) and for the treatment of an HCV infection.
BACKGROUND OF THE INVENTION
It has recently been discovered that certain macrocyclic compounds are potent and specific inhibitors of hepatitis C virus (HCV) protease. In particular, compounds of the following formula I have been found to be an especially potent class of inhibitors against the NS3 serine protease of HCV:
wherein:
designates an optional bond forming a double bond between positions 13 and 14;
R
1
is H, halo, C
1-6
alkyl, C
3-6
cycloalkyl, C
1-6
haloalkyl, C
1-6
alkoxy, C
3-6
cycloalkoxy, hydroxy, or N(R
5
)
2
, wherein each R
5
is independently H, C
1-6
alkyl or C
3-6
cycloalkyl;
R
2
is H, halo, C
1-6
alkyl, C
3-6
cycloalkyl, C
1-6
haloalkyl, C
1-6
thioalkyl, C
1-6
alkoxy, C
3-6
cycloalkoxy, C
2-7
alkoxyalkyl, C
6 or 10
aryl or Het, wherein Het is a five-, six-, or seven-membered saturated or unsaturated heterocycle containing from one to four ring heteroatoms selected from nitrogen, oxygen and sulfur;
said cycloalkyl, aryl or Het being optionally substituted with R
6
, wherein R
6
is H, halo, C
1-6
alkyl, C
3-6
cycloalkyl, C
1-6
alkoxy, C
3-6
cycloalkoxy, NO
2
, N(R
7
)
2
, NH—C(O)—R
7
; or NH—C(O)—NH—R
7
, wherein each R
7
is independently: H, C
1-6
alkyl or C
3-6
cycloalkyl;
or R
6
is NH—C(O)—OR
8
wherein R
8
is C
1-6
alkyl or C
3-6
cycloalkyl;
R
3
is R
9
O— or R
9
NH—, wherein R
9
is C
1-6
alkyl or C
3-6
cycloalkyl;
R
4
is H or from one to three substituents on any available carbon atom at positions 8, 9, 10, 11, 12, 13 or 14, said substituent independently selected from the group consisting of: C
1-6
alkyl, C
1-6
haloalkyl, C
1-6
alkoxy, hydroxy, halo, amino, oxo, thio or C
1-6
thioalkyl;
See Tsantrizos et al., U.S. application Ser. No. 09/760,946, filed on Jan. 16, 2001, (Boehringer Ingelheim (Canada), Ltd.), which application is herein incorporated by reference in its entirety and is hereinafter referred to as “Tsantrizos et al”. See also the corresponding WO 00/59929 (Boehringer Ingelheim (Canada) Ltd.).
A structural feature of the compounds of formula I is the presence of the C-terminal carboxylic acid functionality, which was shown to be responsible not only for the potency and reversibility observed for this inhibitor series, but also for the excellent specificity for HCV protease compared to other serine/cysteine proteases. An HCV serine protease inhibitor such as the compounds of formula I would be expected to be an antiviral agent acting via a novel mechanism, i.e. blockage of a virus-encoded essential function for HCV replication. A drug acting through this mechanism should suppress viral replication of all HCV genotypes and therefore provide tangible benefits to patients with chronic hepatitis C.
A common problem among protease inhibitors is that these compounds are lipophilic and have low aqueous solubility. Because of the poor aqueous solubility, conventional solid and liquid pharmaceutical preparations containing these inhibitors may not be absorbed by the patient in a satisfactory manner. Of the various factors that can affect the bioavailability of a drug when administered orally, (which include aqueous solubility, drug absorption through the gastrointestinal tract, dosage strength and first pass effect), aqueous solubility is often found to be among the most important factors. Poorly water soluble compounds often exhibit either erratic or incomplete absorption in the digestive tract, and thus produce a less than desirable response.
The compounds of formula I are zwitterionic and are capable of forming salts with strong acids and bases. Attempts to identify salts of such compounds in solid forms, which would substantially improve aqueous solubility, have not been successful. Various salts of these compounds have been found to be very hygroscopic, reducing the stability of the compounds. In addition, formulations of salts of these compounds generally are prone to precipitation of the parent free-acid in the gastrointestinal tract. Representative compounds of formula I have shown poor bioavailability when administered to animals as an aqueous suspension, suggesting that conventional formulations containing these inhibitors may not be absorbed in a satisfactory manner. Thus, there is a need in the art for pharmaceutical compositions of the formula I compounds having improved bioavailability.
Methods of formulating certain lipophilic macrocyclic compounds into pharmaceutical formulations have been previously reported. For example, Cavanak, U.S. Pat. No. 4,388,307, discloses the preparation of emulsified formulations of commercially available cyclosporins, and Hauer et. al, U.S. Pat. No. 5,342,625, and Meizner et al. WO 93/20833 disclose the preparation of cyclosporin microemulsions and microemulsion pre-concentrates. Komiya et. al, U.S. Pat. No. 5,504,068, further discloses the preparation of an enhanced topical formulations of cyclosporin.
Examples of “self-emulsifying” formulations of lipophilic compounds include Lipari et al, WO 96/36316, which discloses a self-emulsifying pre-concentrate comprising a lipophilic compound, d-alpha-tocopheryl polyethylene glycol 1000 succinate (TPGS) and a lipophilic phase. Gao et al., U.S. Pat. No. 6,121,313 discloses a self-emulsifying formulation of a pyranone protease inhibitor comprising the pyranone compound, a mixture of mono- and di-glycerides, one or more solvents and one or more surfactants; and Gao et al, U.S. Pat. No. 6,231,887 B1 discloses a self-emulsifying formulation of a pyranone protease inhibitor comprising the pyranone compound, an amine, one or more solvents and one or more surfactants.
Yu et. al U.S. Pat. Nos. 5,360,615 and 5,071,643 disclose the preparation of a solvent system for enhancing the solubility of acidic, basic or amphoteric compounds by partial ionization comprising a mixture of polyethylene glycol, hydroxide or hydrogen ion, and water. Morton et al U.S. Pat. No. 5,376,688 discloses solutions of acidic, basic or amphoteric pharmaceutical agents comprising the pharmaceutical agent, an ionic species and a solvent system. Bhagwat et. al U.S. Pat. No. 6,056,977 teaches the use of polysaccharide based matrix for sustained release of a sulfonylurea.
Despite these advances, there continues to be a need in the art for oral pharmaceutical compositions of the zwitterionic compounds of formula I having improved bioavailability.
BRIEF SUMMARY OF THE INVENTION
The present invention overcomes the aforementioned problems by providing pharmaceutical compositions of the formula I compounds having improved bioavailability as compared to conventional pharmaceutical formulations. In particular, specific compositions of the present invention have demonstrated excellent in vitro dissolution profiles and have achieved marked increases in bioavailability as compared to conventional pharmaceutical formulations.
The pharmaceutical compositions of the present invention cover a wide variety of types of compositions, but all comprise a compound of formula I together with one or more pharmaceutically acceptable amines. The compositions of the present invention may include one or more additional ingredients depending on the type of composition contemplated, e.g., pharmaceutically acceptable solvents, surfactants, oils, polymers, etc., as will be discussed in more detail below. The present invention is also directed to the methods of manufacturing these compositions, as described hereinafter.
In a general embodiment, the pharmaceutical composition of the present invention comprises:
(a) a compound of formula (I):
wherein:
designates an optional bond forming a double bond between positions 13 and 14;
R
1
is H, halo, C
1-6
alkyl, C
3-6
cycloalkyl, C
1-6
haloalkyl, C
1-6
alkoxy, C
3-6
cycloalkoxy, hydroxy, or N(R
5
)
2
, wherein each R
5
is independently
Chen Shirlynn
Mei Xiaohui
Boehringer Ingelheim International GmbH
Datlow Philip I.
Kifle Bruck
Morris Michael
Raymond Robert
LandOfFree
Pharmaceutical compositions for hepatitis C viral protease... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Pharmaceutical compositions for hepatitis C viral protease..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Pharmaceutical compositions for hepatitis C viral protease... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3299279